Tumor-Derived Microparticles to Monitor Colorectal Cancer Evolution

  • Diane Mege
  • Laurence Panicot-Dubois
  • Christophe Dubois
Part of the Methods in Molecular Biology book series (MIMB, volume 1765)


Colorectal cancer is the most common gastrointestinal cancer and the second-most common cause of cancer-related death worldwide. Microparticles are small vesicles known to be implicated in tumor growth, the development of metastases, and cancer-associated procoagulant activity. We have reported a specific hallmark of microparticles in colorectal and pancreatic cancers, the so-called “microparticulosome.” We have also reported on variations in the microparticulosome in the case of the occurrence of a thromboembolic event. Here, we describe our flow cytometry-based methods for identifying and characterizing tumor-derived microparticles and thereby monitoring colorectal cancer evolution.

Key words

Microparticle Tumor-derived microvesicle Colorectal cancer Tissue factor Fibrin 


  1. 1.
    Chew HK, Wun T, Harvey D et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464CrossRefPubMedGoogle Scholar
  2. 2.
    Piccin A, Murphy WG, Smith OP (2007) Circulating microparticles: pathophysiology and clinical implications. Blood Rev 21:157–171CrossRefPubMedGoogle Scholar
  3. 3.
    van Doormaal FF, Kleinjan A, Di Nisio M et al (2009) Cell-derived microvesicles and cancer. Neth J Med 67:266–273PubMedGoogle Scholar
  4. 4.
    Rak J (2010) Microparticles in cancer. Semin Thromb Hemost 36:888–906CrossRefPubMedGoogle Scholar
  5. 5.
    D’Souza-Schorey C, Clancy JW (2012) Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 26:1287–1299CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Thomas GM, Panicot-Dubois L, Lacroix R et al (2009) Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 206:1913–1927CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mezouar S, Darbousset R, Dignat-George F et al (2015) Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer 136:462–475CrossRefPubMedGoogle Scholar
  8. 8.
    Mege D, Panicot-Dubois L, Ouaissi M et al (2016) The origin and concentration of circulating microparticles differ according to cancer type and evolution: A prospective single-center study. Int J Cancer 138:939–948CrossRefPubMedGoogle Scholar
  9. 9.
    Lacroix R, Judicone C, Mooberry M et al (2013) Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 11:1190–1193CrossRefGoogle Scholar
  10. 10.
    Robert S, Lacroix R, Poncelet P et al (2012) High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles—brief report. Arterioscler Thromb Vasc Biol 32:1054–1058CrossRefPubMedGoogle Scholar
  11. 11.
    Lacroix R, Robert S, Poncelet P et al (2010) Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 8:2571–2574CrossRefPubMedGoogle Scholar
  12. 12.
    Mege D, Crescence L, Ouaissi M, Sielezneff I, Guieu R, Dignat-George F, Dubois C, Panicot-Dubois L (2017) Fibrin-bearing microparticles: marker of thrombo-embolic events in pancreatic and colorectal cancers. Oncotarget 8(57):97394–97406Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Diane Mege
    • 1
  • Laurence Panicot-Dubois
    • 1
  • Christophe Dubois
    • 1
  1. 1.Aix Marseille University, INSERM UMR-S1076, C2VNMarseilleFrance

Personalised recommendations